Legend Biotech Corp
NASDAQ:LEGN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.42
69.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Legend Biotech Corp
Wall Street
Price Targets
LEGN Price Targets Summary
Legend Biotech Corp
According to Wall Street analysts, the average 1-year price target for
LEGN
is 84.24 USD
with a low forecast of 60.6 USD and a high forecast of 99.75 USD.
LEGN Last Price Targets
Legend Biotech Corp
The latest public price target was made on Nov 13, 2024 by
Rick Bienkowski
from
Cantor Fitzgerald
,
who expects
LEGN
stock to
rise by 103%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Rick Bienkowski
Cantor Fitzgerald
|
83
USD
Upside 103% |
1 week ago
Nov 13, 2024
|
Legend Biotech Corp. (LEGN) PT Raised to $83 at Cantor Fitzgerald
StreetInsider
|
Gena Wang
Barclays
|
94
USD
Upside 130% |
1 month ago
Oct 15, 2024
|
Barclays Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
StreetInsider
|
|
Justin Zelin
BTIG
|
91
USD
Upside 122% |
1 month ago
Oct 15, 2024
|
BTIG Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
StreetInsider
|
|
Gena Wang
Johnson Rice
|
94
USD
Upside 130% |
1 month ago
Oct 15, 2024
|
Legend Biotech weakness a buying opportunity, says Barclays
TheFly
|
|
Qize Ding
Redburn Partners
|
86
USD
Upside 110% |
1 month ago
Oct 8, 2024
|
Legend Biotech initiated with a Buy at Redburn Atlantic
TheFly
|
Edward Tenthoff
Piper Sandler
|
90
USD
Upside 120% |
5 months ago
Jun 17, 2024
|
Piper Sandler Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
StreetInsider
|
Asthika Goonewardene
Truist Financial
|
88
USD
Upside 115% |
5 months ago
Jun 17, 2024
|
Legend Biotech initiated with a Buy at Truist
TheFly
|
James Shin
Deutsche Bank
|
60
USD
Upside 47% |
6 months ago
May 23, 2024
|
Deutsche Bank Starts Legend Biotech Corp. (LEGN) at Buy
StreetInsider
|
Matthew Harrison
Morgan Stanley
|
82
USD
Upside 100% |
6 months ago
May 17, 2024
|
Legend Biotech Corp. (LEGN) PT Lowered to $82 at Morgan Stanley
StreetInsider
|
Leonid Timashev
RBC Capital
|
86
USD
Upside 110% |
6 months ago
May 14, 2024
|
Legend Biotech price target raised to $86 from $85 at RBC Capital
TheFly
|
George Farmer
Scotiabank
|
65
USD
Upside 59% |
7 months ago
Apr 17, 2024
|
Scotiabank Upgrades Legend Biotech Corp. (LEGN) to Sector Outperform
StreetInsider
|
|
Rick Bienkowski
Cantor Fitzgerald
|
82
USD
Upside 100% |
7 months ago
Apr 3, 2024
|
Cantor Fitzgerald Starts Legend Biotech Corp. (LEGN) at Overweight
StreetInsider
|
Kostas Biliouris
BMO Capital
|
90
USD
Upside 120% |
8 months ago
Mar 14, 2024
|
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is LEGN's stock price target?
Price Target
84.24
USD
According to Wall Street analysts, the average 1-year price target for
LEGN
is 84.24 USD
with a low forecast of 60.6 USD and a high forecast of 99.75 USD.
What is Legend Biotech Corp's Revenue forecast?
Projected CAGR
80%
For the last 5 years the
compound annual growth rate for
Legend Biotech Corp's revenue is
42%.
The projected
CAGR
for the next 3 years is
80%.
You don't have any saved screeners yet
